Core Points - Windtree Therapeutics, Inc. has regained compliance with Nasdaq's minimum bid price requirement, allowing it to continue listing on the exchange [1][2] - The company was previously notified of non-compliance on December 4, 2024, due to its stock closing below 1.00 or more for at least 10 consecutive trading days, which it achieved starting February 21, 2025 [2] Company Overview - Windtree Therapeutics is focused on becoming a revenue-generating biotechnology company, advancing innovative therapies for critical conditions and diseases [3] - The company's product portfolio includes istaroxime, a Phase 2 candidate for acute heart failure, and preclinical candidates for heart failure and oncology applications [3] - Windtree operates a licensing business model with existing partnership out-licenses [3]
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules